Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000317 · ClinicalTrials.gov registry record · Phase 2
Early Phase II Trials for Cocaine Medication Development - 1
A Phase 2 study, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
NCT00000317 is a Phase 2 study that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 31 participants.
The verdict
NCT00000317, a Phase 2 study, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
Study Summary
The purpose of this study is to develop models for early Phase II testing of potential medications for cocaine dependence: amoxapine, risperidone and other agents. The study was a controlled pilot trial of risperidone in opiate-dependent patients on methadone maintenance. The study explored whether risperidone reduced cocaine use, cocaine craving, and cocaine subjective effects in patients on methadone maintenance who abused cocaine and whether it had an acceptable side effect profile. This
Interventions
- DRUG Placebo
- DRUG Risperidone
- BEHAVIORAL Relapse prevention counseling
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 1996-08 |
| Est. Completion | 1999-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00000317
The ClinicalTrials.gov registry entry for NCT00000317 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00000317 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00000317 about?
NCT00000317 is a clinical study titled "Early Phase II Trials for Cocaine Medication Development - 1". The purpose of this study is to develop models for early Phase II testing of potential medications for cocaine dependence: amoxapine, risperidone and other agents. The study was a controlled pilot trial of risperidone in opiate-dependent patients on methadone maintenance. The study explored whether...
What is the current status of trial NCT00000317?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 1996-08. Estimated completion is 1999-07.
What interventions are being tested in trial NCT00000317?
The interventions under investigation include: Placebo (DRUG), Risperidone (DRUG), Relapse prevention counseling (BEHAVIORAL).
Who is sponsoring clinical trial NCT00000317?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.